Unlocking the potential of lumateperone and novel antipsychotics for schizophrenia

S Rehan Ahmad^{1*}, Md Zeyaullah^{2*}, Abdullah M. AlShahrani², Mohammad Suhail Khan³, Adam Dawria³, Ali Mohieldin³, Haroon Ali³, Abdelrhman AG Altijani³, Mohammad Shane Alam⁴, Munzila Mehdi⁵, Sabika Akram⁵, Ejaz Rizvi Hussain⁵, Mohammad Amjad Kamal^{6,7,8}

¹Hiralal Mazumdar Memorial College for Women, West Bengal State University, Kolkata , West Bengal , 700035, India

²Department of Basic Medical Science, College of Applied Medical Sciences, Khamis Mushayt Campus, King Khalid University, Abha 62561, Saudi Arabia

³Department of Public Health, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University, Abha 62561, Saudi Arabia


⁴Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Kingdom of Saudi Arabia, Jizan 45142, Saudi Arabia

⁵Department of Botany, Aligarh Muslim University, Uttar Pradesh, Aligarh 202002, India


⁶Joint Laboratory of Artificial Intelligence in Healthcare, Institutes for Systems Genetics and West China School of Nursing, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610000, Sichuan Province, China

⁷Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh


⁸Enzymoics, 7 Peterlee place, Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia




(1A)













(1B)



(1D)



(1F)




Figure S1 - 2D structure from PUBCHEM of all mentioned drugs in this paper where (1A = Lumateperone), (1B=Brexpiprazole), (1C= Brilaroxazine), (1D= F17464), (1E=Pimavanserin), (1F=Roluperidone), (1G= Xanomeline), (1H=BI 409306), (1I=BI 425809) (1J=MK-8189)

Table S1- Comprehensive Table on Different Anti-psychotic Drugs underclinical trials

Drug	Mecha	Dosage	Dosage	Efficacy	and	Unique	Side	Current	Referenc
name	nism of	forms	regimens	clinical	trials	characteristi	effects	scenari	es
	action			results		CS		0	

Luma teper one	Agonis t at presyn aptic D2 recept ors and an antago nist at postsy naptic D2 recept ors	Oral (Tablet)	10.5 mg, 21 mg, and 42 mg, with the typical daily dose being 42 mg	In Phase I Lumatepero ne did not show any adverse effect as well in phase I1 and in phase II patient symptoms decreased and patient get stable with 60 mg under III and phase II trial	Show promising responses towards dopaminer gic, serotonergi c, and glutamater gic neurotrans mission for the relief of symptoms of diiferent neuropsych iatric disorders	Constipati on, sedation, fatigue, and somnolen ce are common side effects and hyperglyc emia, orthostati c hypotensi on, leukopeni a, neutropen ia, malignant syndrome, tardive dyskinesi a, EPS, and dyslipide mia are serious side effects	Trials are going on related to safety and long- term efficacy	5,23,24
Brexp ipraz ole	Agonis t D2 recept ors	Oral (Tablet)	Under trial so dosage is not finalized yet	2-4 mg of Brexpiprazol e is more effective in combination and reduce severe symptoms	Brexpipraz ole exhibits lower intrinsic activity as an agonist than aripiprazol e.	Sleeplessn ess, weight gain, hypertens ion, and anxiety are prevalent side effects	Curren tly clinical trials are going on teenag ers and its prevale nt side effects	48,55,56
Brilar oxazi ne	High- affinit y partial agonis	Oral (Tablet)	Under trial so dosage is not finalized	15 mg and 50 mg of Brilaroxazin e show positive	It also acts on D2, D3, and D4 receptors with	EPS and akathisiaa re common side	Phase II trial is comple te and	59

	t on seroto nin 5- HT1A and 5- HT2A recept ors		yet	result in Phase II	similar chemical structure like aripiprazol e	effects and increased liver enzymes is severe side effects	phase III has not started yet	
F174 64	Agonis t of 5- HT1A recept ors while acting as a D3 antago nist	Not Clear, mostly oral (tablet)	Under trial so dosage is not finalized yet	20 mg BD of F17464 show positive result in Phase II	Remain detectable at D3 receptors for up to 22 h post- treatment, supporting its suitability for twice- daily dosing	Sleeplessn ess, agitation, hyperlipid emia, and akathisia are side effect reported	Cogniti ve ability assess ment of F17464 is going on	62,65
Pimav anser in (ACP- 103)	Invers e agonis t at the 5HT2A recept or with high affinit y and lower affinit y for dopam ine recept ors	Not Clear	Under trial so dosage is not finalized yet	Pimavanseri n reverse psychosis like behaviour without exacerbating motor difficulties in Parkinson's Disease and in phase II and III trial does not improve PANSS score	Used for treating psychosis in Parkinson's disease (PD)	Pimavans erin show side effects nausea, periphera l edema, confusion, hallucinat ions, constipati on, and gait disturban ce	Multipl e trials are going on to assess tolerab ility and effectiv eness of pimava nserin	67,68,77 ,78
Rolup erido ne	5- HT2A inhibit or and a sigma two recept or antago	Not Clear, mostly oral (tablet)	During trial 32 mg and 64 mg of roluperid one was used	Roluperidon e reduce schizophreni a symptoms in Phase II and III trials but during phase III trial dosage is bit high	Act as an alpha1- adrenergic antagonist little affinity for muscarinic, cholinergic, and histaminer	During phase II trial serious side effects like vomiting, abdomina l pain,	Trials are going on related to safety and long- term	79,80,85

	nist				gic receptors	syncope and bradycard ia	efficacy	
Xano melin e	Musca rinic activat or primar ily affecti ng M1 and M4 recept or subtyp es	Not Clear, mostly oral	Under trial so dosage is not finalized yet	Xanomeline in combination with trospium decreases PANSS overall scores	Exhibit functional dopamine antagonism	Xanomeli ne show adverse effects like nausea, puking, pain in the gastrointe stinal tract, salivation, diarrhoea, and constipate d and Xanomeli ne in combinati on with trospium show seious adverse effect which is not disclosed	Xanom eline and in combin ation with trospiu m show is going on to overco me advers e effects	86,87
BI 4093 06	PDE9A inhibit ory agent	Not Clear	Under trial so dosage is not finalized yet	BI 409306 did not improve MATRICS Consensus Cognitive Battery (MCCB)	PDE9A inhibition boost intracellula r cGMP availability and NMDA receptor signalling, improving synaptic plasticity and memory function in Alzheimer's Disease	Eye abnormali ties like blurred vision, photopho bia, visual brightness , flashes, and colour disruption are observed in Phase II trial	Trials halted during pande mic and till date no trial or investi gation started	90,93

					(AD)			
BI 4258 09	Preven t Glycin e transp orter 1 (GlyT1), and impro ving glutam ate's effect on NMDA recept ors	Not Clear, mostly oral	During trial 10 mg and 25 mg is used but need to be finalized	show any positive	Focus on cognition and memory in disorders like AD and half- life of more than 30 hour	Side effects like headaches , drowsines s, and problems with the digestive tract with reduced hemoglobi n level noticed but no EPS	No further update as till phase III no promis ing result	93,94,95
MK- 8189	Phosp hodies terase 10A inhibit or modifi es the dopam ine D1- direct and D2- indirec t striata l pathw ays and contro ls striata l glutam ate recept or phosp horyla	Not Clear, mostly oral (tablet)	During phase II trial 16 and 24 mg dosages but need to be finalized		Half-life of 7.6 to 10.9 hr	Final findings of NCT03565 068 on MK-8189 has not been released	Extensi ve phase II trial is being conduc ted to evaluat e MK- 8189 at 16 and 24 mg dosage s	103,104, 108

tion
